Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -21.80% is 25% below its 3-year average of -17.47%, near the low end of its 3-year range (-26.06%–-9.92%).
As of the fiscal period ended Tuesday, June 30, 2026. 7.47% below its 12-month average of -20.29%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -21.80%.
RETURN ON EQUITY (ROE)
-21.80%
RETURN ON EQUITY (ROE) AVG TTM
-20.29%
RETURN ON EQUITY (ROE) AVG 3Y
-17.47%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-7.47%
CURRENT VS 3Y AVG
-24.80%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.30%
median of 668 covered companies
CURRENT VS SECTOR MEDIAN
+45.91%
vs the sector median at left
CG Oncology Inc.
Market Cap
$5.68B
Return on Equity (ROE)
-21.80%
TTM Avg
-20.29%
3Y Avg
-17.47%
5Y Avg
N/A
Market Cap
$5.73B
Return on Equity (ROE)
12.33%
TTM Avg
0.28%
3Y Avg
12.51%
5Y Avg
-14.51%
Market Cap
$5.54B
Return on Equity (ROE)
-1.93%
TTM Avg
-0.70%
3Y Avg
0.57%
5Y Avg
0.69%
Market Cap
$5.51B
Return on Equity (ROE)
-9.09%
TTM Avg
-8.34%
3Y Avg
-4.98%
5Y Avg
-4.98%
Market Cap
$5.91B
Return on Equity (ROE)
20.38%
TTM Avg
5.87%
3Y Avg
3.40%
5Y Avg
3.36%
Market Cap
$5.88B
Return on Equity (ROE)
-39.33%
TTM Avg
-54.18%
3Y Avg
-65.89%
5Y Avg
-59.69%
Market Cap
$6.02B
Return on Equity (ROE)
-15.40%
TTM Avg
-48.41%
3Y Avg
-63.30%
5Y Avg
-53.67%
Market Cap
$5.33B
Return on Equity (ROE)
18.24%
TTM Avg
20.62%
3Y Avg
17.32%
5Y Avg
27.02%
Market Cap
$5.30B
Return on Equity (ROE)
N/A
TTM Avg
-149.71%
3Y Avg
-15.45%
5Y Avg
-6097.55%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CG Oncology Inc. (CGON) | $5.68B | -21.80% | -20.29% | -17.47% | N/A |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.73B | 12.33% | 0.28% | 12.51% | -14.51% |
| RadNet, Inc. (RDNT)vs › | $5.54B | -1.93% | -0.70% | 0.57% | 0.69% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.51B | -9.09% | -8.34% | -4.98% | -4.98% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.91B | 20.38% | 5.87% | 3.40% | 3.36% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.88B | -39.33% | -54.18% | -65.89% | -59.69% |
| GRAIL Inc. (GRAL)vs › | $6.02B | -15.40% | -48.41% | -63.30% | -53.67% |
| Doximity, Inc. (DOCS)vs › | $5.33B | 18.24% | 20.62% | 17.32% | 27.02% |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.30B | N/A | -149.71% | -15.45% | -6097.55% |
| Sotera Health Company (SHC)vs › | $5.28B | 24.56% | 11.91% | -7.82% | -3.31% |
ROE
-21.8%
ROA
-20.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -21.80% |
| 2026-03-31 | -17.10% |
| 2025-12-31 | -21.39% |
| 2025-09-30 | -22.03% |
| 2025-06-30 | -19.11% |
| 2025-03-31 | -14.98% |
| 2024-12-31 | -12.00% |
| 2024-09-30 | -13.48% |
| 2024-06-30 | -11.54% |
| 2024-03-31 | -9.92% |
| 2023-12-31 | -26.06% |
| 2023-09-30 | -20.23% |
